Amid Warfarin Inertia, Bristol/Pfizer Price Eliquis On Par With Pradaxa
This article was originally published in The Pink Sheet Daily
Eliquis is set to become widely available in the U.S. market at the end of January, with pricing similar to other new oral anticoagulants, despite competitive advantages. Cost and safety concerns help explain why warfarin continues to dominate the market.
You may also be interested in...
US payers may increasingly look to leverage the competition among the novel oral anticoagulants by contracting for preferred coverage with two of the leading drugs in the field, rather than all three.
Bad press and lawsuits related to bleeding events for Boehringer Ingelheim’s novel anticoagulant Pradaxa create a window of opportunity for Eliquis, which is pending approval in the U.S. and could have what it takes to tip the market away from generic warfarin.
Data from the pilot program a “driving factor” in the agency’s decision against changing its recommendations for the blood thinner following reports of increased serious bleeding events.